Market Overview

R.F. Lafferty Devalues Auxilium, QLT Deal

Related AUXL
Drug ETFs Attractive Buys On Pullback
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients

R.F. Lafferty graded Auxilium Pharmaceuticals' (NASDAQ: AUXL) acquisition of QLT (NASDAQ: QLT) to be neutral, based on lack of sufficient cash for Auxilium to complete the deal.

Auxilium announced on Thursday that it will acquire QLT for 3.1359 shares of Auxilium stock, equivalent to a 25 percent premium based on QLT's stock price on June 25, 2014. The merger is expected to close later in the fourth quarter of 2014.
Despite the deal announced to be a stock-for-stock deal, Auxilium lacking the cash power could mean that acquiring QLT creates an opportunity cost, making the deal less valuable.

Shares of Auxilium dropped 3.93 percent to $20.43 in the middle of Thursday's market hours. Shares have rebounded in Friday's action, up less than one percent to $20.76.

Latest Ratings for AUXL

DateFirmActionFromTo
Oct 2014MKM PartnersDowngradesBuyNeutral
Oct 2014Mizuho SecuritiesDowngradesBuyNeutral
Sep 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

Posted-In: R.F. LaffertyAnalyst Color Analyst Ratings

 

Related Articles (AUXL + QLT)

Around the Web, We're Loving...

Get Benzinga's Newsletters